Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.

NCT00846196 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00846196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00846196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.
Lead sponsor
Warner Chilcott
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
May 31, 2009
Enrollment
538 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis